See more : Tose Co., Ltd. (4728.T) Income Statement Analysis – Financial Results
Complete financial analysis of SELLAS Life Sciences Group, Inc. (SLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SELLAS Life Sciences Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Asseco Poland S.A. (ACP.WA) Income Statement Analysis – Financial Results
- NexPoint Real Estate Finance, Inc. (NREF-PA) Income Statement Analysis – Financial Results
- Yintai Gold Co., Ltd. (000975.SZ) Income Statement Analysis – Financial Results
- Senior plc (SNIRF) Income Statement Analysis – Financial Results
- Alexander & Baldwin, Inc. (ALEX) Income Statement Analysis – Financial Results
SELLAS Life Sciences Group, Inc. (SLS)
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.00M | 7.60M | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.32M | 2.49M | 2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 100.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 355.00K | 1.40M | 520.00K | 0.00 | 20.79M | 0.00 | 0.00 | 0.00 | 11.41M | 0.00 |
| Gross Profit | 0.00 | 900.00K | 7.40M | 1.90M | 0.00 | 0.00 | 0.00 | -3.00K | -355.00K | 7.92M | 1.97M | 2.04M | -20.79M | 0.00 | 0.00 | 0.00 | -11.41M | 0.00 |
| Gross Profit Ratio | 0.00% | 90.00% | 97.37% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 84.94% | 79.09% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.01M | 30.27M | 21.37M | 9.28M | 7.29M | 18.32M | 6.07M | 19.86M | 23.61M | 28.35M | 21.08M | 14.61M | 11.54M | 7.87M | 8.89M | 7.05M | 6.75M | 1.30M |
| General & Administrative | 13.86M | 12.58M | 11.32M | 9.60M | 9.92M | 12.77M | 15.09M | 12.01M | 10.61M | 31.34M | 14.60M | 6.59M | 6.86M | 8.75M | 8.63M | 4.87M | 3.74M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.39M | 0.00 | 0.00 | 2.63M | 931.00K | 0.00 |
| SG&A | 13.86M | 12.58M | 11.32M | 9.60M | 9.92M | 12.77M | 15.09M | 12.01M | 10.61M | 31.34M | 14.60M | 6.59M | 9.25M | 8.75M | 8.63M | 7.50M | 4.67M | 633.00K |
| Other Expenses | 0.00 | 10.00M | 5.70M | 0.00 | 0.00 | -3.03M | 0.00 | 0.00 | 509.00K | 170.00K | 37.00K | -13.18M | 9.25M | 0.00 | 0.00 | 7.50M | 0.00 | 0.00 |
| Operating Expenses | 37.87M | 42.85M | 32.69M | 18.88M | 17.21M | 31.09M | 21.16M | 31.87M | 34.22M | 60.14M | 35.81M | 21.20M | 20.79M | 16.63M | 17.52M | 14.55M | 11.41M | 2.41M |
| Cost & Expenses | 37.87M | 42.95M | 32.89M | 18.88M | 17.21M | 31.09M | 21.16M | 31.87M | 34.22M | 61.54M | 36.33M | 21.20M | 20.79M | 16.63M | 17.52M | 14.55M | 11.41M | 2.41M |
| Interest Income | 525.00K | 317.00K | 6.00K | 26.00K | 118.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 180.00K | 448.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 118.00K | 266.00K | 462.00K | 3.51M | 760.00K | 1.11M | 807.00K | 33.00K | 0.00 | 5.00K | -5.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 37.87M | 457.00K | 1.27M | 377.00K | 17.21M | 22.04M | 3.00K | 3.00K | 355.00K | 440.00K | 452.00K | 49.00K | 163.00K | 172.00K | 162.00K | 131.00K | 36.00K | 0.00 |
| EBITDA | 529.00K | -31.95M | -19.66M | -16.40M | 668.00K | 0.00 | -23.04M | -15.99M | -37.48M | -36.61M | 7.63M | -34.38M | -11.32M | -11.82M | -18.22M | -14.24M | -10.93M | -2.41M |
| EBITDA Ratio | 0.00% | -4,228.20% | -390.08% | -888.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -733.32% | 306.71% | -1,040.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -37.87M | -41.95M | -25.29M | -16.98M | -20.04M | -31.09M | -23.04M | -31.87M | -34.22M | -52.22M | -33.84M | -21.20M | -20.79M | -16.63M | -17.52M | -14.55M | -11.41M | -2.41M |
| Operating Income Ratio | 0.00% | -4,195.00% | -332.82% | -893.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -560.38% | -1,360.68% | -1,040.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 529.00K | 649.00K | 4.36M | 208.00K | 668.00K | 2.54M | -7.79M | 5.13M | -4.37M | 13.62M | -41.79M | -13.18M | 9.30M | 4.63M | -867.00K | 180.00K | 448.00K | 0.00 |
| Income Before Tax | -37.34M | -41.30M | -20.94M | -16.77M | -19.37M | -29.05M | -23.50M | -10.86M | -38.59M | -36.61M | -75.63M | -34.38M | -11.49M | -11.99M | -18.39M | -14.37M | -10.97M | -2.41M |
| Income Before Tax Ratio | 0.00% | -4,130.10% | -275.47% | -882.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -392.81% | -3,040.85% | -1,686.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -649.00K | -237.00K | -17.00K | -81.00K | -1.38M | 253.00K | 243.00K | 365.00K | -15.45M | 1.05M | -1.05M | -9.30M | -4.63M | 867.00K | 0.00 | 25.00K | 0.00 |
| Net Income | -37.34M | -40.65M | -20.70M | -16.76M | -19.29M | -27.67M | -23.75M | -23.55M | -63.90M | -36.61M | -76.68M | -34.97M | -11.49M | -11.99M | -18.39M | -14.37M | -10.99M | -2.41M |
| Net Income Ratio | 0.00% | -4,065.20% | -272.36% | -881.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -392.81% | -3,083.15% | -1,715.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.34 | -2.10 | -1.34 | -2.10 | -7.54 | -105.80 | -507.49 | -3.55K | -12.35K | -9.20K | -25.51K | -16.80K | -9.48K | -19.60K | -34.05K | -31.38K | -26.04K | -5.73K |
| EPS Diluted | -1.34 | -2.10 | -1.34 | -2.10 | -7.54 | -105.80 | -507.49 | -3.55K | -12.35K | -9.20K | -25.51K | -16.80K | -9.48K | -19.60K | -34.05K | -31.38K | -26.04K | -5.73K |
| Weighted Avg Shares Out | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 46.81K | 6.64K | 5.17K | 3.98K | 3.01K | 2.08K | 1.21K | 612.00 | 540.00 | 458.00 | 422.00 | 420.00 |
| Weighted Avg Shares Out (Dil) | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 46.81K | 6.64K | 5.18K | 3.98K | 3.01K | 2.08K | 1.21K | 612.00 | 540.00 | 458.00 | 422.00 | 420.00 |
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April -
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
- Update on the Phase 3 REGAL Clinical Trial of GPS in Acute Myeloid Leukemia (AML) - - Update on the Phase 2a Clinical Trial of SLS009 in relapsed/refractory AML, including topline data - NEW YORK, March 19, 2024 (GLOBE...
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
- All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met - - Complete remission (CR) achieved after three months of treatment with duration of eight months and one year survival at the latest assessment - -...
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
The FDA bestows a Fast Track Designation to SELLAS' (SLS) pipeline candidate, SLS009, for the treatment of relapsed/refractory acute myeloid leukemia. Stock gains.
Source: https://incomestatements.info
Category: Stock Reports